Stay updated on Precision 1 Clinical Trial: Nab-sirolimus in TSC1/TSC2 Gene Tumors

Sign up to get notified when there's something new on the Precision 1 Clinical Trial: Nab-sirolimus in TSC1/TSC2 Gene Tumors page.
Latest website image capture
Clouds background image

Latest updates to the Precision 1 Clinical Trial: Nab-sirolimus in TSC1/TSC2 Gene Tumors page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-14T01:53:07.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value for the Primary Completion Date has been updated from (Estimated) 7 to 8. This change indicates a potential adjustment in the expected completion date for the study.
    Difference
    0.1%
    Check dated 2024-06-06T15:58:23.000Z thumbnail image
  7. Check
    12 days ago
    Change Detected
    Summary
    The value 'Recruiting' has recently changed to 'Active, not recruiting' on the webpage, indicating a shift in the status of the clinical trial from actively recruiting participants to no longer recruiting as of the estimated date 06 03 31.
    Difference
    28%
    Check dated 2024-06-04T07:14:30.000Z thumbnail image
  8. Check
    25 days ago
    Change Detected
    Summary
    The value of Participation Criteria has been updated on the webpage. The change now includes detailed eligibility criteria for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes, identified using NGS in tumor tissue or liquid biopsy.
    Difference
    20%
    Check dated 2024-05-22T07:21:41.000Z thumbnail image
  9. Check
    26 days ago
    Change Detected
    Summary
    The value '03 13 Recruiting Contact : Fiona Davidson fiona.davidson@prismahealth.org Principal Investigator : William Edenfield, MD 03 12 03 13 02' has recently changed to '05 20 Active, not recruiting 05 17 (Estimated) 05 20 05.' This change indicates that the study has transitioned from recruiting to an active, not recruiting phase.
    Difference
    0.6%
    Check dated 2024-05-21T03:47:16.000Z thumbnail image
  10. Check
    46 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2024-04-30T22:43:55.000Z thumbnail image

Stay in the know with updates to Precision 1 Clinical Trial: Nab-sirolimus in TSC1/TSC2 Gene Tumors

Enter your email address, and we'll notify you when there's something new on the Precision 1 Clinical Trial: Nab-sirolimus in TSC1/TSC2 Gene Tumors page.